Andrew Reardon, who serves as Chief Legal Officer and Secretary of Ligand Pharmaceuticals Inc., completed a sale of 5,000 shares of common stock on June 1, 2026. The total value realized from this divestiture was $1,135,315. During the transaction, the selling price for the shares ranged between $223.9467 and $230.41 per share.
This reported sale comes against a backdrop of substantial gains in Ligand Pharmaceuticals' stock performance. Over the past year, the company's shares have increased by 129%. The current trading price is noted at $233.01, which places it near its 52-week high of $247.38.
Market analysis from InvestingPro suggests that, relative to its Fair Value estimate, the stock currently appears overvalued based on existing metrics.
The sale was preceded by an acquisition of similar shares by Mr. Reardon. On the same date, he acquired 5,000 shares of Ligand Pharmaceuticals common stock through the exercise of employee stock options. These newly acquired shares were purchased at a cost of $52.27 per share, amounting to a total investment of $261,350.
Crucially, all transactions reported for Mr. Reardon, encompassing both the initial option exercise and the subsequent sale of shares, were conducted pursuant to a pre-arranged trading plan. This plan was adopted by him on November 24, 2025, adhering to Rule 10b5-1 guidelines.
Details regarding the underlying stock options reveal that they were part of a larger grant. A portion of this grant vested on February 1, 2023, representing 12.5% of the total shares. The remaining shares are scheduled to vest through 42 substantially equal monthly installments following that date. These employee stock options carry an expiration date set for August 1, 2032.
Following the completion of these reported transactions, Andrew Reardon's direct holdings of Ligand Pharmaceuticals common stock were calculated to be 41,382 shares.
Recent Corporate and Financial Developments
Beyond insider activity, recent filings provide insight into the company's operational and strategic direction. In a development concerning earnings, Ligand Pharmaceuticals reported its first-quarter results for 2026. These quarterly figures did not meet the expectations set by financial analysts.
Specifically, the adjusted earnings per share (EPS) posted was $1.63. This figure fell short of the projected estimate of $1.84, representing an 11.41% negative surprise for investors. Furthermore, Ligand's revenue reached $51.72 million. This amount was below the anticipated revenue of $59.07 million, resulting in a significant 12.44% revenue shortfall.
In terms of corporate restructuring and strategic partnerships, Ligand Pharmaceuticals also provided an amendment to its merger agreement with XOMA Royalty Corporation. This amendment, which is dated May 16, 2026, formally includes XOMA Royalty Holdings Corporation as a party to the overall agreement. Under the revised framework outlined in the amendment's terms, Flex Merger Sub, Inc., which operates as a wholly owned subsidiary of Ligand, will execute a merger with XOMA’s recently established Nevada corporation, HoldCo. The outcome of this planned combination dictates that HoldCo will subsequently become a wholly owned subsidiary of Ligand Pharmaceuticals.
Analysis and Market Context
The confluence of these events presents a mixed picture for the company. While Mr. Reardon's transactions were structured under established regulatory plans, signaling adherence to compliance procedures, the underlying financial metrics reported suggest challenges. The significant misses in both EPS and revenue indicate that operational performance did not align with market predictions.
The strategic merger amendment with XOMA Royalty Corporation points toward ongoing corporate development, solidifying relationships between subsidiaries. These developments are part of a broader set of recent activities surrounding Ligand Pharmaceuticals' financial structure and future plans.